PDF(Pubmed)
Abstract：
Postpartum depression (PPD) impairs mother-infant interaction and has negative effects on the child\'s emotional, behavioral, and cognitive skills. There is considerable evidence to suggest that inflammation plays a role in the pathogenesis of depression. Controlled trials indicate that celecoxib has antidepressant effects in patients with major depressive disorder. A 34-year-old woman with mild to moderate PPD received a celecoxib capsule twice a day. This treatment has not been reported in previous studies and is novel in clinical practice. The patient was assessed using the Hamilton Depression Rating Scale (HDRS). Moreover, levels of brain-derived neurotrophic factor (BDNF) and inflammatory cytokines were measured at baseline and at the end of celecoxib therapy. This case suggests that celecoxib can improve depressive symptoms in patients with mild to moderate PPD. No adverse effects occurred during follow-up.
摘要：
产后抑郁症（PPD）损害母婴互动，对孩子的情绪有负面影响，行为，和认知技能。有大量证据表明炎症在抑郁症的发病机理中起作用。对照试验表明，塞来昔布对重度抑郁症患者具有抗抑郁作用。一名34岁的女性患有轻度至中度PPD，每天两次接受塞来昔布胶囊。这种治疗在以前的研究中没有报道，在临床实践中是新颖的。使用汉密尔顿抑郁量表（HDRS）评估患者。此外，在基线和塞来昔布治疗结束时测量脑源性神经营养因子(BDNF)和炎性细胞因子的水平.该病例表明塞来昔布可以改善轻度至中度PPD患者的抑郁症状。随访期间无不良反应发生。
